title: Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team.
abstract: One hundred eighty-one antiretroviral-experienced, protease inhibitor-naive, clinically stable HIV-infected children between 4 months and 17 years of age were randomly assigned to receive one of four combination regimens to evaluate the change in plasma HIV RNA, safety, and tolerance when changing antiretroviral therapy to a protease inhibitor-containing combination regimen. All four regimens contained stavudine; in addition children received nevirapine plus ritonavir, lamivudine plus nelfinavir, nevirapine plus nelfinavir, or lamivudine plus nevirapine plus nelfinavir. Twelve additional children chose to receive stavudine plus lamivudine plus nelfinavir, with nelfinavir given bid, rather than tid as for the main regimens. Overall, 51% (89/176; 95% CI 43-58%) of the children on the randomized portion of the study had an HIV RNA response (< or =400 copies/ml) on at least two of the three HIV RNA determinations taken at Weeks 8, 12, and 16. At Week 24 the proportion of children with an HIV RNA response still on initial therapy was 47% (83/176; 95% CI 40-55%) and ranged from 41 to 61% for the four randomized treatment arms. Rash was frequently seen (27%) on the treatment arms containing nevirapine. At Week 24 64% (7/11, 95% CI 31-89%) of the children on the bid nelfinavir combination regimen were still on initial therapy with an HIV RNA response as compared with 46% (23/50; 95% CI 32-61%) on the corresponding tid nelfinavir combination regimen. A change in antiretroviral therapy to a protease inhibitor-containing regimen was associated with a virological response rate of approximately 50% for this patient population.
authors.affiliation: Pediatric HIV Services, Jacobi Medical Center, Bronx, New York 10461, USA. wiznia@worldnet.att.net
authors.forename: A
authors.initials: A
authors.lastname: Wiznia
authors.forename: K
authors.initials: K
authors.lastname: Stanley
authors.forename: P
authors.initials: P
authors.lastname: Krogstad
authors.forename: G
authors.initials: G
authors.lastname: Johnson
authors.forename: S
authors.initials: S
authors.lastname: Lee
authors.forename: J
authors.initials: J
authors.lastname: McNamara
authors.forename: J
authors.initials: J
authors.lastname: Moye
authors.forename: J B
authors.initials: JB
authors.lastname: Jackson
authors.forename: H
authors.initials: H
authors.lastname: Mendez
authors.forename: R
authors.initials: R
authors.lastname: Aguayo
authors.forename: A
authors.initials: A
authors.lastname: Dieudonne
authors.forename: A
authors.initials: A
authors.lastname: Kovacs
authors.forename: M
authors.initials: M
authors.lastname: Bamji
authors.forename: E
authors.initials: E
authors.lastname: Abrams
authors.forename: S
authors.initials: S
authors.lastname: Rana
authors.forename: J
authors.initials: J
authors.lastname: Sever
authors.forename: S
authors.initials: S
authors.lastname: Nachman
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D005006:Ethnicity; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D008297:Male; D019888:Nelfinavir / Q000627:therapeutic use*; D019829:Nevirapine / Q000627:therapeutic use*; D011647:Puerto Rico; D012367:RNA, Viral / Q000097:blood; D044469:Racial Groups; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D019438:Ritonavir / Q000627:therapeutic use*; D018119:Stavudine / Q000627:therapeutic use*; D013997:Time Factors; D014481:United States; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine; D018119:Stavudine; D019888:Nelfinavir; D019438:Ritonavir